Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $608.2 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 29.84% year-over-year to $608.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 billion (down 21.01% YoY), and the FY2025 full-year result was $715.7 million, down 21.2% from the prior year.
• Liabilities and Shareholders Equity fell to $608.2 million in Q1 2026, from $715.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $967.5 million in Q1 2024 to a low of $150.9 million in Q1 2023.
• A 5-year average of $560.8 million and a median of $608.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 541.19% in 2024 and dropped 29.84% in 2026, its largest moves.
• Tracing VKTX's Liabilities and Shareholders Equity over 5 years: stood at $168.5 million in 2022, then soared by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then slipped by 21.2% to $715.7 million in 2025, then fell by 15.02% to $608.2 million in 2026.
• Business Quant data shows VKTX's Liabilities and Shareholders Equity at $608.2 million in Q1 2026, $715.7 million in Q4 2025, and $739.4 million in Q3 2025.